Celerion appoints vp of Global Bioanalytical Services

Will run bioanalytical operations in Zurich and Lincoln, Nebraska

Celerion, a US-based provider of early stage drug development solutions, has hired Raymond Farmen as vice president of Global Bioanalytical Services. He takes responsibility for bioanalytical operations in Zurich, Switzerland and Lincoln, Nebraska, US.

Farmen has more than 30 years of experience in the contract research organisation (CRO) and pharmaceutical industries. Prior to joining Celerion, he held executive positions at PharmOptima, a CRO specialising in ocular research services; Eurofins AvTech Laboratories, a small and large molecule bioanalytical chemistry specialist; and Camargo Pharmaceutical Services, which provides scientific and regulatory oversight during the drug development process.

You may also like

Research & Development

Celerion receives a 2017 CRO leadership award in multiple categories for clinical research excellence

Celerion, a leading clinical research organisation, is pleased to announce it has received a CRO Leadership Award for the fourth time by global biopharmaceutical executives in Life Science Leader’s annual CRO Leadership Awards for 2017
Containment

Celerion adds Containment Room at Belfast facility

Will allow firm to carry out live biologics and vaccine studies
Research & Development

Celerion adds bronchoscopy suite in Belfast

Allows brochoalveolar lavage (BAL) to be performed using a multiplex approach
Research & Development

Celerion expands ADME suite in Lincoln, Nebraska

Now able to carry out on-site scintillation counting
Research & Development

Celerion and Ricerca Biosciences to provide integrated service for biosimilars

Will test viability of a potential biosimilar early in the process
Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence
Research & Development

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
Subscribe now